In light of the 2016 update of the WHO brain tumor classification that stipulates an integrated, ‘layered’ diagnosis based on histological and molecular features9, isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations play a key role in the classification of gliomas. This evidence concerns the gene IDH2 and central nervous system cancer.